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Abstract: GBM (Glioblastoma) is the most common, malignant type of primary brain 
tumor. It has a dismal prognosis, with an average life expectancy of less than 15 months. 
A better understanding of the tumor biology of GBM has been achieved in the past 
decade and set up new directions in the multimodal therapy by targeting the molecular 
paths involved in tumor initiation and progression. Invasion is a hallmark of GBM, and 
targeting the complex invasive mechanism of the tumor is mandatory in order to achieve 
a satisfactory result in GBM therapy. The goal of this review is to describe the tumor 
biology and key features of GBM and to provide an up-to-date overview of the current 
identified molecular alterations involved both in tumorigenesis and tumor progression.  
Key words: glioblastoma, molecular pathways, invasion, targeted therapy. 
 
Introduction 
Malignancies involving the Central 
Nervous System (CNS) are undoubtedly a 
diagnostic and therapeutic challenge. Among 
them, High-grade gliomas, are by far the most 
challenging issue for neurosurgeons and neuro 
oncologists. Glioblastoma is the highest-grade 
glioma tumor (WHO grade IV) [65], the most 
common type of primary malignant brain 
tumor in humans [43, 15], and one of the 
deadliest cancers. Despite extensive efforts to 
streamline the methods of diagnosis and 
treatment, GBM remains the neurosurgeon’s 
Eternal Hydra [84] and an invariably lethal 
tumor with a median survival of 15-17 months 
[101], despite maximal therapy. The standard 
of care [11] for patients with newly diagnosed 
GBM encompasses maximal safe surgical 
resection, if feasible, or stereotactic/open 
biopsy if tumor resection is not an option, 
followed by radiation therapy plus 
concomitant and adjuvant chemotherapy with 
Temozolomide. Unfortunately the standard 
treatment for patients with GBM remains 
palliative; it is virtually impossible to "cure" 
GBM, as complete resection is possible in only 
few cases and recurrence is diagnosed in as 
much as 83% of the patients [9]. The failure of 
standard therapy in GBM is reflected by the 
recurrence rates, a highly aggressive tumor 
behavior in relapses and the poor overall 
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patient prognosis. If we had to choose one 
word to describe GBM it would likely be 
heterogeneity that is reflected not only from a 
clinical, gross-morphological or 
histopathological perspective but also in terms 
of genetic, molecular and newer, proteomic, 
perspectives [76, 58]. Genotyping of brain 
tumors may have applications in stratifying 
patients for clinical trials of various novel 
therapies [94]. Cytogenetic and molecular 
analysis of the tumor along with robust animal 
models [1] set a new direction in 
understanding tumor pathogenesis and in 
developing a complex multimodal therapeutic 
sequence. In 2008 The Cancer Genome Atlas 
research team (TCGA) which aims at 
establishing a database of high-resolution 
expression profiles in tumors, choose GBM as 
the path breaker tumor [67]. A future genetic 
classification of brain tumors, derived from 
the technical tour de force of gene microarrays 
will provide a useful database and the path to 
improve results in cancer therapy [54]. A 
thorough understanding of the tumor biology 
and especially of the complex invasive and 
migratory mechanism of GBM is mandatory 
in order to develop a new generation of 
targeted, highly specific therapies and to fight 
"The Terminator ", as GBM is often called [41]. 
Epidemiology, clinical features and imaging  
GBM is the most frequent type of primary 
brain malignancy, with an overall incidence 
rate of 3.19 per 100,000 person-years in USA 
[15] and 3.32 (CI, 2.69–4.09) for male cases 
and 2.24 (CI, 1.56–3.22) for female cases, age-
adjusted to the World Standard Population as 
showed by a population-based study on 
glioblastoma in the Canton of Zurich, 
Switzerland [75]. The highest incidence rates 
of GBM are found in the 6th and 7th decades 
of life. Primary and secondary glioblastoma 
constitute distinct disease subtypes- the 
majority of cases (>90%) are primary 
glioblastomas that develop rapidly -de novo, 
while secondary glioblastomas develop 
through progression from low-grade, diffuse 
astrocytoma or anaplastic astrocytoma, 
manifest in younger patients, and have 
different genetic pathways [76] and prognosis 
[27]. Data suggest that older age, male gender 
and higher socio economic status, increase the 
risk for GBM [16]. 
In the majority of cases, the clinical 
presentation of glioblastoma is superposable 
on that of all intracranial expansive processes, 
expressing the progressively increased 
intracranial pressure against the 
incompressible compartment of the skull, as 
stated by the Monroe Kellie doctrine [70]. 
Common findings include: persistent 
headache, papilledema, incoercible vomiting, 
ocular palsies, altered level of consciousness. 
The clinical elements of glioblastoma can be 
summarized in general and focal signs 
(hemiparesis, sensory loss, visual loss, 
aphasia). Of the clinical elements is 
distinguished by frequency: headaches, as a 
constant finding [31], neurocognitive 
impairments and seizures.  There are however 
a number of issues suggestive for an 
underlying GBM: the most remarkable aspect 
is the galloping pace of progression and 
worsening of symptoms (clinical 
manifestations in primary glioblastoma have a 
duration of <3 months to >50% of patients at 
the time of diagnosis [12], and the mean 
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period from first symptoms to histological 
diagnosis is around 6 months. The clinical 
picture of GBM depends on several aspects: 
the location of the tumor and adjacent 
structures involved in tumor expansion, the 
rhythm of tumor progression, the marked 
invasive behavior, a hallmark for GBM, 
bleeding - either within the tumor 
(glioblastomas are strongly vascularized 
tumors, with an impressive potential of 
neoangiogenesis), or bleeding in other 
vascular structures secondarily involved in the 
extending - infiltrative lesion, the existence of 
multifocal lesions, patient age and 
comorbidities. There have been reported cases 
with atypical clinical features such as ulnar 
neuropathy, syncopal events [93], or even 
sudden unexpected death [88]. The progress of 
medical imaging tools, today owning a 
remarkable degree of accuracy in describing 
different types of lesions, decreased the 
importance of a thorough clinical approach in 
order to establish the topography of the tumor. 
However, we always must pay attention to the 
"warning signs" that alert on the possibility of 
an evolving tumor process: 1) any signs or 
symptoms that suggest a progressively 
increased ICP; 2) any evolving neurological 
deficit; 3) occurrence of epilepsy in adult 
life[109]; and mostly an accelerated worsening 
in any above - suggestive for an underlying 
GBM . 
 GBM is a "colorful but deadly tumor" [80], 
with pleomorphic aspects in imaging tools- 
findings. Usually CT-scan is the first step in 
the imaging investigations. It usually describes 
an iso/hypo dense lesion with irregular 
boundries and a central hypodense area that 
reflects the necrosis [79]. Peritumoral edema 
and bleeding areas within the lesion are also 
constant findings. Despite important 
improvements in CT-scan technique [21], 
MRI is the best choice [26] to describe the 
morphology of the tumor, as CT-scan can miss 
posterior fossa lesions-despite it's not a 
common topography for GBM, it can also 
overpass small tumors that fail to capture the 
contrast agent. The preoperative imaging 
modality of choice is gadolinium-enhanced 
magnetic resonance imaging (MRI) [35]. 
Other imaging modalities, such as positron 
emission tomography with (18F)-fluoro-
deoxy-d-glucose or SPECT-MRI, may also be 
considered in selected cases [24]. However the 
standard MRI-approach has its limits: viable 
tumor areas extend beyond the region signal 
switch, therefore the magnitude of tumor 
extension and infiltration cannot be assessed 
accurately by MRI studies. The indefinable 
borders of glioblastoma cell infiltration into 
the surrounding healthy tissue prevent 
complete surgical removal. Another drawback 
of MRI studies is that sometimes fail to 
distinguish post-treatment radiographic 
imaging changes [113] the so called 
"pseudoprogression” from true tumor 
progression [103]-underlying once more the 
need for improvement in the tumor imaging 
field. 
From stem to GBM  
Over time there have been questioned 
some ethiopathogenic hypotheses about GBM, 
each having a number of arguments more or 
less sustainable with scientific evidence.  
Initially it was thought that glioblastoma 
tumor cells derive from embryonic primitive 
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cells - the embrional remains theory of Bailey 
and Cushing (1926), which dominated the 
tumor pathogenesis for many years [4] and 
encompasses the general concept that cancers 
arose from embryo-like cells, which remained 
in a tissue. Subsequently came the astrocyte 
origin-theory, a prominent theory that 
encompasses the idea that this tumors arise 
from neoplastic transformation of mature 
adult cells (dedifferentiation)-brought into 
perspective by Kernohan, suggesting that a 
normal astrocyte is transformed into a 
neoplastic cell by "escaping" certain points in 
the cell cycle and gaining resistance to 
apoptosis by blocking apoptotic pathways in 
cells-becoming malignant cells. As it 
multiplies, the daughter cells become variably 
anaplastic [91].  
However, it is currently thought that high-
grade gliomas arise from more primitive 
elements, specifically stem cells, and it may be 
that the ostensible dedifferentiation is an 
artifact of the histologic appearance of tumors. 
The characterization of a fraction of tumor 
cells in many types of cancer (colon, breast, 
blood, brain) opened a new chapter in cancer 
research, providing a new, hierarchic model of 
malignancy for GBM. Cancer stem cell can 
become specific targets that can be 
incorporated into the development of 
multimodal therapeutic strategies. Cancer 
stem cells have been identified in GBM and 
some pediatric brain tumors - especially 
medulloblastoma [29, 111]. This fraction of 
cells is different from the bulk tumor cells by 
several aspects: they own an abnormal 
expression of cellular pathways such as Notch 
or stat3 and they are somehow resistant to 
classic therapy- chemo-resistant and resistant 
to radiation therapy. Stem cells theory in 
gliomagenesis [92] practically revolutionized 
the concept of GBM tumor ontogeny. The idea 
that states the absence of neural regenerative 
potential may be considered invalid by the 
results of recent research [98, 59]. On top of 
this pyramid is a cell group possessing a 
distinctive behavior-neural stem cells. This cell 
population permits the tumor survival, but the 
cells are also involved in the highly invasive 
nature characteristic of this type of tumor. 
Neural stem cells population   provides the 
"fuel" for the invasive behavior of the tumor. It 
raises naturally the question about the origin 
of these stem cells and the extent to which 
these cell populations normally reside in 
certain areas of the CNS, and the event that 
triggers malignant transformation of stem 
cells. In certain types of malignancies that 
develop in this stem-model (the so called "stem 
cells disease") such as chronic myeloid 
leukemia [8] it is clear that these malignant 
stem cells arise from normal hematopoietic 
stem cells that undergo a series of genetic 
mutations and epigenetic changes. The major 
attribute of these cells is the ability to self-
renewal [110], but first we have to find out 
what is "self" in terms of stem cells. However, 
the actual existence and features [93] of stem 
cells - not only neural stem cells but also stem 
cells that reside in other parts of the body is 
subject of controversy - as  "seeing is believing" 
and no one yet succeeded to "catch " a stem cell 
under the microscope. What we have is a 
functional pattern for a stem cell, based on 
several phenotypic markers, the self-renewal 
ability being by far the most important aspect 
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that brings into perspective a possible stem - 
cell emergence for GBM. 
Underlying genetic alterations in tumor 
initiation  
Malignant astrocytomas, and particularly 
glioblastoma, have a number of common 
characteristics with the rest of malignancies, 
features that generally define the hallmarks of 
cancer [37]: (1)  the ability of cancer cells to 
stimulate their own growth; (2) the capacity to  
resist inhibitory signals that might otherwise 
stop their growth; (3) they resist their own 
programmed cell death (apoptosis); (4) they 
stimulate the growth of blood vessels to supply 
nutrients to tumors (angiogenesis); (5) they 
can multiply forever-potential 
immortalization with telomerase activation 
and (6) they invade local tissue and spread to 
distant sites (metastasis). GBM is a unique 
type of tumor, owing a very heterogeneous cell 
population, genetic and molecular pathways. 
In addition, another 4 cardinal aspects must be 
taken into account in understanding possible 
gliomagenesis: 1) abnormal metabolic 
pathways; (2) evading the immune system; (3) 
chromosome abnormalities and unstable 
DNA; and (4) inflammation. Following we try 
to present an integrated, evidence - based view, 
on what we know about GBM pathways, 
tailored on what we recognize as oncogenic 
events in general.  
One of the main features of cancer 
ontogeny is genomic instability [63]. This 
feature can take many forms: aneuploidy or 
intimate changes in chromosomal structure 
are equally frequent. One of the most common 
chromosomal abnormality in GBM is the loss 
of heterozygosity [85]. The most frequent 
involved regions, as shown by hybridization 
studies, are: p, 6q, 9p, 10p, 10q, 13q, 14q, 15q, 
17p, 18q, 19q, 22q, and Y [53] .By far the most 
common finding is the loss of heterozygosity 
at 10 q level, ocuuring in 60- 80 % of the cases. 
Loss of the heterozygous nature turns the 
hemizygotysm area in a vulnerable area. 
Extensive studies found at least three distinct 
loci to be deleted at 10q level (e.g., 10p14–p15, 
10q23–24, distal to 10q25) while some 
samples show a complete loss of a copy of 
chromosome 10 underlying once more the 
pleomorphic nature of GBM. Integrating the 
main features of a malignant behavior - and 
the findings that show this type of aneuploidy 
(as PTEN mutation is almost exclusively find 
in cases with LOH) - we can strongly suggest 
the possibility of tumor suppressor genes 
residing in this loci, and mark the genomic 
instability as the first hot spot gliomagenesis. 
The cell cycle encompasses a fine regulated 
sequence of biochemical processes, which is 
supervised by a very accurate structure the so 
called - "cell cycle control system" [3]. RB 
pathway and p53, among others, are the 
"guardians" of the cell cycle- the key players in 
tumor suppressing activity. Disturbances in 
cell cycle are the background of enhanced, 
uncontrolled cell proliferation. The tumor 
suppressing genes involved in RB 
(retinoblastoma) or p53 pathway [33], are 
either inactivated or encounter mutational 
defects [28, 95, 19] in GBM cases (loss of 
chromosome 9 which contains CDKN2A, 
CDKN2B, and PTPRD genes involved in p53 
and RB pathways is also identified in some 
cases). There is also strong evidence that 
genetic alterations in the PTEN tumor 
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suppressor gene on 10q23 - become involved 
in this "mutational gained tumor 
independence". Some data suggest even fine 
interactions between PTEN, p53, and RB 
pathways contributory to this anarchic 
proliferation as a result of a damaged 
suppressing activity [28]. Summarizing, we 
can argue the existence of a second hot spot in 
tumor biology at the cell cycle control level 
with the respective complex mechanisms 
involved. 
Any cellular structure whose volume 
exhibits 2-3 cm3 cannot virtually survive 
without a proper vascular backup. The 
processes of neo-angiogenesis [13] is a cancer 
hallmark and is highly accelerated in GBM 
adjusted to the speeding rhythm of growth and 
is mediated by fine mechanism that involve 
growth factors, and other local mechanism 
[44]. Amplification of the epidermal growth 
factor receptor (EGFR) gene on chromosome 
7 is also a habitual finding in GBM. EGFR gene 
amplification or mutation and subsequent 
activation of the PI3K/AKT pathways is found 
in 30-40 % of primary GBM. EGFR is a cell 
membrane receptor - that is normally found in 
many cells. EGFR and its ligands are expressed 
in variable proportions even during 
embryogenesis in the neural tissue and persists 
in postnatal and mature brain. Abnormal 
expression or altered signaling of growth 
factors and their respective pathways is a 
common theme in GBM. Altered function of 
EGFR, VEGF, PDGR, and TGF have all been 
implicated in GBM. Moreover, up regulation 
of EGFR was identified in a number of other 
cancers [74] (lung cancer, breast cancer, colon 
cancer), all above reputed in terms of 
malignancy. A majority of EGFR 
amplifications in glioblastoma contain a 
mutant variant of EGFR, that is EGFRviii [25, 
34] and is linked to a dismal prognosis [39]. 
Murine glioma models confirmed the 
involvement of EGFR in gliomagenesis. Also 
deletion of NFKBIA [89] (an EGFR signaling 
inhibitor) [10] is related to a poor prognosis. 
As an important aspect, EGFR amplifications 
and mutation scarcely occur in secondary 
GBM, suggesting different mechanism 
involved in the two types of GBM [106]. All 
above bring forward a third hot spot at the 
growth factor paths level. 
New data suggest that GBM de novo and 
secondary GBM can be regarded as completely 
different tumors each having an individual 
path of progression with just discreet overlap 
sequences [76]. IDH1 encodes isocitrate 
dehydrogenase 1 and is involved in energy 
metabolism. IDH1 mutations have been 
predominantly identified in secondary 
glioblastoma and low-grade gliomas [46], with 
mutations in more than 70% of cases and they 
are found only sporadically in primary 
glioblastoma [107]. Therefore, IDH1 could be 
used to differentiate primary from secondary 
glioblastoma, and moreover highlights 
abnormal cellular metabolic pathways as a 
fourth hot spot in tumor activity. 
Current research data provide a multitude 
of presumed hot spots in GBM tumor 
initiation and progression that put into 
perspective possible new therapies [105] for 
this unique type of tumor. Studies by The 
Cancer Genome Atlas (TCGA) have 
incorporated genomic alterations within 
expression analysis, and set molecular 
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subclasses in high-grade glioma, delineating a 
pattern of disease progression that resembles 
stages in neurogenesis, and have been used to 
classify glioblastoma into: proneural, neural, 
classic, and mesenchymal subtypes [82]. 
Different subtypes of glioblastoma have been 
shown to behave differently in response to 
treatment [9]. 
GBM invasion - one direction - several 
molecular "vehicles" 
GBM is highly invasive by nature, it can be 
regarded as a referential model of malignancy. 
First, the tumor has an important local 
extension [51], the rapid, diffuse, infiltration 
of adjacent structures, and secondly there is a 
metastatic potential [62, 66]  though not a 
common situation  for GBM - occurring  
especially in patients undergoing surgical 
procedures [42], which create  favorable local 
conditions  for dissemination and not least 
there are situations  of multifocal tumors [2] in 
patients diagnosed with GBM - situations  that 
beyond the  radiological diagnosis and coarse 
morphological description,  question the 
possible existence of synchronous, 
methachronous  tumors or  the expression of 
complex mechanisms  of invasion within the 
brain [5] - still unsolved- so that the multifocal 
appearance could be a particular model of 
invasion [72]. In the local extension of GBM, 
there have been observed “selective routes" - 
primarily it is known that the extension is 
elective in the brain parenchyma - in different 
white matter structures depending on the 
specific topography of the primary tumor. The 
majority of supratentorial glioblastoma are 
localized in the cerebral hemispheres - with 
epicenter in full white matter [1]. Elective 
extension in the white matter [14] is argued by 
the fact that despite the highly invasive profile 
of the tumor, subarachnoid extension is rarely 
seen in glioblastoma- metastasis through the 
cerebrospinal fluid is exceptional. Migrating 
glioma cells tend to move along the vessels, 
dendrites, and fibers in white matter. A 
preferred extension route used by GBM is the 
corpus callosum - the tumor extends into the 
contralateral hemisphere generating a 
spectacular morphology, a symmetric bilateral 
transcallosal lesion described as "butterfly 
glioma". Cerebral white matter myelin 
structure and the elective white matter-routes 
(internal capsule, fornix, etc.) in GBM local 
extension opens the hypothesis of alterations 
at the cohabitation mechanisms level between 
- glial cells and the myelin sheet. Normally, 
besides structural proteins, in myelin structure 
there are a number of proteins with highly 
specific functions, called neurite growth 
inhibitors NI35/250- that inhibit the abnormal 
axonal regeneration, growth and proliferation 
of astrocytes and fibroblasts. Blocking the 
abovementioned with monoclonal antibodies 
led to a "leak" at the white matter level - as in 
vitro and in vivo studies show [14]. These 
white matter findings may be suggestive for 
the existence of an alteration in the mechanism 
of NI35/250 dampening in determining the 
invasive behavior of tumor cells particularly in 
the white matter. These characteristics suggest 
that GBM possesses specific biological 
mechanisms that mediate its invasive nature 
[57]. A sequential approach was proposed as a 
model of invasion [64]: 1) detachment of cells 
with invasive potential from the main tumor 
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mass 2) adhesion to extracellular matrix 3) 
degradation of the extracellular matrix 4) cell 
motility and contractility to integrate the 
infiltrated territory and further migration. In 
this sequence, there have been identified 
several "key-molecules". Some presumed 
signaling pathways to invasion are linked to 
constitutive cell-membrane proteins such as: 
RTK (EGFR, PDGFR), Integrins [87, 104] and 
CD44 [112, 77]. Overexpression of these 
membrane proteins, among other molecules is 
linked to GBM invasion. 
The primary event - the detachment of cells 
from the primary tumor - involves a series of 
events that lead in a first phase to an unstable 
status of the cell in the tumor 
microenvironment. This event was blamed on 
the links provided by cadherin disintegration 
[20]. Cadherin provide a Ca2 +-dependent 
transmembrane protein involved in cell 
adhesion, which contributes to the 
stabilization of the tissue cells. Abnormal high 
expression of cadherin 11 was identified in 
GBM, especially near vascular structures [50, 
81]. The pivotal cell or cells so destablished 
from the bulk tumor, can initiate the invasive 
path. 
Continuing the invasive trajectory of the 
detached cells involves metalloproteinase   
activity (MMP) respectively MMP-2 and 
MMP-9 proteolytic activity which "destroy" 
barriers in the path of matrix invasion, while 
adaptive integration in microclimate is 
ongoing [30], as MMP are considered to be key 
regulators of the microclimate [52]. Moreover, 
levels of MMP-2 and MMP-9 are considered 
the strongest predictors of glioblastic invasive 
potential [108]. However, it also raises the 
question of the selective high activity of these 
endopeptydase and orientation of the 
migratory route preferential toward areas 
discussed, as we still don't have a referential 
pattern of normal MMP in neural tissue, so 
that we can't shape an explanation of this 
"polarization" of the cell invasive route.  
The cell that migrates from the bulk tumor 
in the invasive GBM model, must have two 
fundamental characteristics: contractility and 
motility. Myosin 2 is the substrate supposed to 
accomplish these 2 features. The migratory cell 
must adapt his diameter to fit in spaces even 
smaller than its nuclear diameter [6]. Isoforms 
A and B of myosin 2 are those which allow 
performing these narrow areas. Involvement 
of myosin 2 expression in invasive type 
behavior has been proved by the positive 
results of direct blocking of myosin 2 in 
counteracting GBM invasion [47]. 
 
  
Figure 1 - The modern diagnostic sequencing for 
GBM 
 
Going deeper into the tumor cell biology 
we can refer to transcription factors involved 
in abnormal pathways. As next-generation 
  
 
 
 
 Romanian Neurosurgery (2015) XXIX (XXII) 1: 3 - 19          11 
 
 
 
 
 
 
 
sequencing technologies are emerging, 
transcriptome description brings into 
perspective new key-molecules in GBM 
invasion. A transcription factor is a structure 
that binds to a specific DNA region and 
controls the activity of selected genes. 
Transcription factors are overactive in cancer 
cells [23] and they are strong candidates as 
targets for future specific molecular therapies 
in cancer [102]: (1) the NF-kappaB and AP-1 
families of transcription factors, 2) the STAT 
family members and 3) the steroids receptors 
are just some examples [60]. Transcription 
factor Olig2 is often expressed in 
oligodendroglia and in “transit-amplifying 
cells” of the subventricular zone, the presumed 
site of most adult neural stem/progenitor cells. 
Olig2 is frequently found in NG2-positive glia 
and is required for development of these cells. 
NG2 is a chondroitin sulfate proteoglycan that 
is thought to be another marker of 
oligodendrocyte progenitor cells. Olig2 
promotes the proliferation of both neural 
progenitors and GBM stem cells by repressing 
the p21 tumor suppressor [61]. TWIST is 
another transcription factor whose abnormal 
activity is related with GBM invasion- 
underlying a mesenchymal change in 
promoting invasion [18] by a process called 
epithelial to mesenchymal transition [69]. This 
would help the cells detached from the 
primary lesion to survive and further infiltrate 
the trajectory. TWIST1 is also a strong 
candidate as a target molecule for future 
therapies.
 
TABLE 1 
Key molecules involved in GBM invasion and the underlying mechanism 
Molecule 
CD44 
Function 
mediates ECM adhesion 
RHAMM mediates ECM adhesion 
MMP9 CD44 cleavage=> ECM adhesion; degradation of ECM 
ADAM proteases  CD44 cleavage=>ECM adhesion 
Integrins avB3 and avB5 ECM adhesion and cytoscheletal rearrangement 
FAK and Pyk 2 cytoplasmic mediators for integrins=> ECM adhesion 
MMP2  degradation of ECM 
cadherin 11 detachment of the cells from the tumor 
EGFR increases MMP1 expression=>degradation of ECM 
PTEN/PI3K/AKT pathway regulation of MMP activity=>ECM adhesion and rearrangement, PTEN 
mutation is linked to an invasive phenotype 
myosin II cell contractility and motility 
tf Olig2 and TWIST cell integration in the migration path  
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This sequential model has a number of 
evidence-based arguments, and brings into the 
line a number of issues regarding GBM 
complex invasive mechanism, and further puts 
into perspective molecular therapeutic 
directions. But there are some obscure issues 
that remain to be elucidated as for example the 
probability of micro-regional heterogeneity in 
the extracellular matrix, the importance of co-
expression and co-activation of surface 
receptors with consequent activation of 
cellular signaling mechanisms to initiate an 
invasive type of behavior, the exact order of 
any phase of the invasion and to what extent 
there is an overlap sequence in all above. 
State of the art in the treatment of GBM 
Genetic mutations, epigenetic 
modifications and micro-environmental 
heterogeneity cause resistance to radio- and 
chemotherapy altogether resulting in a hardly 
to overcome therapeutic scenario. Multiple 
challenges remain in high-grade gliomas 
management [83]. Upon initial diagnosis of 
glioblastoma, standard treatment consists of 
maximal surgical resection, radiotherapy, and 
concomitant and adjuvant chemotherapy with 
Temozolomide [11, 35] (in selected cases less 
aggressive therapy is employed-patients older 
than 70 years undergo radiation therapy or 
Temozolomide alone). 
Patients should be evaluated by a 
specialized multidisciplinary team: antiepiletic 
drugs are prescribed for seizures; steroid-
therapy, with glucose level monitoring; a 
careful assessment of the patients's ability to 
perform activity of daily living or to undergo 
therapy - Karnofsky performance status scale 
can be used, all above are important 
therapeutic aspects- maintenance of quality of 
life should be the key end-point of the therapy 
[40]. 
Surgery is an integral part of GBM 
treatment [90]. Surgical removal of the 
glioblastoma by craniotomy can be beneficial 
for some people, both to alleviate symptoms 
associated with the tumor and to extend 
survival following radical removal. Also the 
only accurate diagnosis of GBM relies on 
biopsy sample. The only way to be sure that a 
brain tumor is a glioblastoma is by looking 
directly at the tumor tissue-either by 
performing an open surgery procedure or by 
stereotactic means. Fluorescence guidance in 
resection of malignant glioma has been shown 
to improve extent of resection and 6-month 
progression-free survival in a prospective, 
multi-institutional clinical and preliminary 
experience in the United States has confirmed 
the high correlation of this fluorescence with 
imaging and histologic features [99]. Of course 
that the outcome of surgical treatment in 
patients with GBM is highly influenced by 
tumor topography [97], extension [10] and the 
actual extent of the surgical resection [78]. 
Moreover, the extent of surgical resection is an 
independent prognostic factor-an analysis of 
28 studies found a mean duration of survival 
advantage of total over subtotal resection for 
glioblastoma (14 vs. 11 month) [48]. 
  The pivotal study of Stupp [101] in NEJM 
marked the split between pre and post 
Temozolomide era in the treatment of GBM. 
We can analyze the difference between the two 
periods in terms of survival [49, 22]: the 
median survival of patients treated with 
surgery and a regimen of radiation therapy was 
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12.0 months while patients who underwent 
surgical procedures, radiation therapy plus 
Temozolomide was 31.9 months. Before 
Temozolomide, Glioblastoma has been viewed 
as a chemo-resistant tumor. Temozolomide is 
currently used in the majority protocolos for 
GBM treatment [17].  Adjuvant external-beam 
RT is well established in the postoperative 
treatment [56, 68].The addition of 
radiotherapy to surgery has been shown to 
increase survival from 3-4 months to 7-12 
months [100].The responsiveness of 
glioblastoma to radiotherapy is highly 
variable. In many instances, radiotherapy can 
induce tumor remission, often marked with 
stability or regression of neurologic deficits as 
well as diminution in the size of the contrast-
enhancing mass, but the period of response is 
short-lived because the tumor typically recurs 
within 1 year, resulting in further clinical 
deterioration and the appearance of an 
expansive region of contrast enhancement 
[45]. Alternative forms of fractionation have 
been investigated. Several studies have 
reported no improvements in terms of 
survival, but also no increased toxicity was 
found. Escalating doses beyond 60 Gy has not 
been shown to be of value. 
   In May 2009 FDA approved 
Bevacizumab for the treatment of 
Glioblastoma, as a single agent for patients 
with progressive disease following prior 
therapy. Bevacizumab is a vascular endothelial 
growth factor-specific angiogenesis inhibitor. 
The reasoning for using it in GBM resides in 
tumor pathogenesis, as mentioned before, one 
of the defining characteristics of GBM is an 
abundant and aberrant vasculature [38]. In a 
simple approach - we try "to starve" the tumor 
by attacking his vascular backup. Since 2009, 
several Phase 2 studies and retrospective series 
have demonstrated that Bevacizumab 
significantly increased six-month progression-
free survival [55] in patients with recurrent 
GBM and may do so in new-onset GBM [36]. 
Bevacizumab can be used as a single-agent 
therapy and in combination therapy with 
cytotoxic agents, specifically Irinotecan with 
no clear superiority among either regimen 
[71]. But despite general enthusiasm regarding 
Bevacizumab, in 2013 a Phase III, 
international study showed that it failed to 
increase overall survival (OS) or statistically 
significant progression-free survival (PFS) for 
Glioblastoma patients in the frontline setting. 
The randomized, double-blind, placebo-
controlled study enrolled 637 patients all of 
whom were newly diagnosed with 
glioblastoma. Participants underwent surgery 
to resect some or most of the tumor, received 
the standard of care of chemo-radiation with 
Temozolomide, and were randomized to 
receive either Bevacizumab or placebo. The 
study was designed with two primary 
endpoints: PFS and OS [32]. So that the real 
benefit of Bevacizumab for patients with newly 
diagnosed GBM is still unclear [73]. 
Conclusion 
New approaches for the management of 
GBM are necessary. A further understanding 
of the tumor pathways and enrollment of 
patients into clinical trials will generate new 
information regarding investigational 
therapies.  All efforts should be directed to 
achieve not only a better overall prognosis, but 
  
 
 
 
14          Grigore et al          Current perspectives concerning the multimodal therapy in Glioblastoma 
 
 
 
 
 
 
 
to get quality years of life for glioblastoma 
patients. 
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